The Wuhan SARS-CoV-2-What's next for China.

Lu, Hongzhou; Stratton, Charles W; Tang, Yi-Wei

Lu, Hongzhou; Stratton, Charles W; Tang, Yi-Wei.

Lu H; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Stratton CW; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Tang YW; Cepheid, Danaher Diagnostic Platform, Shanghai, China.

J Med Virol ; 92(6): 546-547, 2020 06.

Article in English | MEDLINE | ID: covidwho-142840

Subject(s)

Betacoronavirus/pathogenicity; Communicable Disease Control/organization & administration; Coronavirus Infections/epidemiology; Disease Outbreaks; Pneumonia, Viral/epidemiology; Antiviral Agents/chemical synthesis; Antiviral Agents/therapeutic use; Betacoronavirus/drug effects; Betacoronavirus/genetics; COVID-19; COVID-19 Vaccines; China/epidemiology; Coronavirus Infections/diagnosis; Coronavirus Infections/prevention & control; Coronavirus Infections/therapy; Coronavirus Infections/transmission; Disease Management; Humans; Pandemics; Pneumonia, Viral/diagnosis; Pneumonia, Viral/therapy; Pneumonia, Viral/transmission; SARS-CoV-2; Travel/statistics & numerical data; Viral Vaccines/biosynthesis

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Communicable Disease Control / Disease Outbreaks / Coronavirus Infections / Betacoronavirus Type of study: Diagnostic study / Observational study Topics: Vaccines Limits: Humans Country/Region as subject: Asia Language: English Journal: J Med Virol Year: 2020 Document Type: Article Affiliation country: Jmv.25738

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google